Diurnal Group PLC Director Dealings and Issue of Equity (3368K)

TIDMDNL

RNS Number : 3368K

Diurnal Group PLC

21 April 2020

21 April 2020

Diurnal Group plc

("Diurnal" or the "Company")

Director Dealings and Issue of Equity

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the following share dealings by Directors:

John Goddard, Non-Executive Director, was today issued and allotted 12,963 new Ordinary Shares at an effective price of nil pence per Ordinary Share as part of a pre-existing arrangement whereby he receives shares in the Company in lieu of part of his Non-executive director fees, issued from the Company's Employee Benefit Trust. Following the transaction, John Goddard has a total interest of 188,589 Ordinary Shares, representing 0.2% of the enlarged total voting rights in the Company.

Application will be made for admission of the 12,963 new Ordinary Shares, which is anticipated to occur at 8:00am on Monday 27 April 2020 ("Admission"). The New Ordinary Shares rank pari passu with the existing shares of the Company. Following issue of the New Ordinary Shares, the Company's issued ordinary share capital consists of 121,633,387 ordinary shares. The Company does not hold any shares in treasury. Therefore, the total number of ordinary shares with voting rights is 121,633,387.

The above figure of 121,633,387 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Details of the full notifications received by the Company are set out below:

 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                   John Goddard 
      -------------------------------------  ----------------------------------------- 
 2     Reason for the notification 
      -------------------------------------------------------------------------------- 
 a)    Position/status                        Non-executive Director 
      -------------------------------------  ----------------------------------------- 
 b)    Initial notification                   Initial notification 
        /Amendment 
      -------------------------------------  ----------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      -------------------------------------------------------------------------------- 
 a)    Name                                   Diurnal Group plc 
      -------------------------------------  ----------------------------------------- 
 b)    LEI                                    213800I2HNUNZN1LDH29 
      -------------------------------------  ----------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      -------------------------------------------------------------------------------- 
 a)    Description of the                     Ordinary shares of 5 pence each in 
        financial instrument,                  Diurnal Group plc 
        type of instrument 
 
       Identification code                    GB00BDB6Q760 
 
 b)    Nature of the transaction              Acquisition of ordinary shares 
      -------------------------------------  ----------------------------------------- 
 c)    Price(s) and volume(s) 
                                              -------------------  ----------------- 
                                               Price(s)             Volume(s) 
                                              -------------------  ----------------- 
    Nil                                                             12,963 
   --------------------------------------------------------------  ----------------- 
 
 d)    Aggregated information 
 
  - Aggregated volume                    As above 
 
  - Price 
 
 e)    Date of the transaction                21 April 2020 
      -------------------------------------  ----------------------------------------- 
 f)    Place of the transaction               XLON 
      -------------------------------------  ----------------------------------------- 
 
 
 For further information, please visit www.diurnal.co.uk or 
  contact: 
 
                                                   [phone] 
 Diurnal Group plc                                  1000 
 Martin Whitaker, Chief Executive Officer 
 Richard Bungay, Chief Financial Officer 
 
 Panmure Gordon (UK) Limited (Nominated Adviser    [phone] 
  and Joint Broker)                                 2500 
 Corporate Finance: Freddy Crossley, Emma Earl 
 Corporate Broking: James Stearns 
 
                                                   [phone] 
 Cantor Fitzgerald Europe (Joint Broker)            7000 
 Corporate Finance: Phil Davies, Will Goode, 
  Michael Boot 
 Healthcare Equity Sales: Andrew Keith 
 
                                                   [phone] 
 FTI Consulting (Media and Investor Relations)      1000 
 Simon Conway 
 Victoria Foster Mitchell 
 

Notes to Editors

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-headquartered, European-based specialty pharma company developing pharmaceutical products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHFIFIASLILFII

(END) Dow Jones Newswires

April 21, 2020 05:05 ET (09:05 GMT)